Literature DB >> 15174950

Recent advances in natriuretic peptides in congestive heart failure.

Guido Boerrigter1, John C Burnett.   

Abstract

Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15174950     DOI： 10.1517/13543784.13.6.643

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


  26 in total

Review 1.  Membrane guanylyl cyclase receptors: an update.

Authors:  David L Garbers; Ted D Chrisman; Phi Wiegn; Takeshi Katafuchi; Joseph P Albanesi; Vincent Bielinski; Barbara Barylko; Margaret M Redfield; John C Burnett
Journal:  Trends Endocrinol Metab       Date:  2006-06-30       Impact factor: 12.015

Review 2.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 3.  Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure.

Authors:  Clyde W Yancy
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  The Mechanism of Action of LCZ696.

Authors:  Juan Tamargo Menendez
Journal:  Card Fail Rev       Date:  2016-05

Review 5.  Critical Questions about PARADIGM-HF and the Future.

Authors:  Chen-Huan Chen
Journal:  Acta Cardiol Sin       Date:  2016-07       Impact factor: 2.672

Review 6.  Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.

Authors:  M Volpe; G Tocci; A Battistoni; S Rubattu
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-06-23

7.  Treatment with B-type natriuretic peptide for chronic decompensated heart failure: insights learned from the follow-up serial infusion of nesiritide (FUSION) trial.

Authors:  Clyde W Yancy
Journal:  Heart Fail Rev       Date:  2004-07       Impact factor: 4.214

Review 8.  The multifaceted role of natriuretic peptides in metabolic syndrome.

Authors:  Prasanna K Santhekadur; Divya P Kumar; Mulugeta Seneshaw; Faridoddin Mirshahi; Arun J Sanyal
Journal:  Biomed Pharmacother       Date:  2017-06-07       Impact factor: 6.529

Review 9.  Molecular and physiological effects of nesiritide.

Authors:  S Reichert; A Ignaszewski
Journal:  Can J Cardiol       Date:  2008-07       Impact factor: 5.223

10.  Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity.

Authors:  Kazutoshi Miyashita; Hiroshi Itoh; Hirokazu Tsujimoto; Naohisa Tamura; Yasutomo Fukunaga; Masakatsu Sone; Kenichi Yamahara; Daisuke Taura; Megumi Inuzuka; Takuhiro Sonoyama; Kazuwa Nakao
Journal:  Diabetes       Date:  2009-08-18       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.